PATH, the Seattle-based global health nonprofit, said it has formed a collaboration with Netherlands-based Crucell and London-based GlaxoSmithKline to develop a next-generation malaria vaccine. The effort will bring together two vaccine approaches in an attempt to improve upon Glaxo’s RTS,S, a vaccine that has shown an ability to protect about half of people who get immunized against malaria. The collaboration will focus on using a single dose of a Crucell vaccine candidate, followed by two doses of RTS,S, in what is known as the “prime-boost” strategy to trigger immune defenses. Terms of the partnership weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
